GLP-1, Active form Assay Kit

Catalog number: 27784-96Well
Brand: IBL Japan
Packing: 96well
Price: On Request
Expected delivery time: 10 days

Product specifications for - GLP-1, Active form Assay Kit

Product group: Assays
Category: ELISA / EIA
Species: Human, Mouse, Rat
Conjugation: HRP
Assay Sample Type: EDTA-plasma
Assay Detection Range: 1.25 ~ 80 pmol/L
Datasheet: Datasheet
  Research Use Only
UNSPSC: 41116158
Form supplied: 1kit
Scientific information: 
Scientific info: Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating. They also inhibit glucagon release from the alpha cells of the islets of Langerhans. As a result, they slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and Gastric inhibitory peptide (or glucose-dependent insulinotropic polypeptide or GIP). The human proglucagon gene was cloned in 1983, and the human proglucagon sequence was subsequently deduced. After that, it was found that the specific sequence of GLP-1 has insulinotropic effect: GLP-1 (7-36) amide. Now, GLP-1 (7-36) amide and GLP-1 (7-37) are known as active forms of GLP-1. They are rapidly inactivated to GLP-1 (9-36) amide and GLP-1 (9-37) by DPP-IV within a few moments in blood. This ELISA kit can measure active forms of GLP-1 (GLP-1 (7-36) amide and GLP-1 (7-37)) specifically.
Additional information: 
Synonyms: 27784; IBL Japan; GLP-1 Active form Human, Mouse, Rat ELISA; GIP / GLP-1 / Insulin / Incretin
Nakaoku Y, Saito S, Yamamoto Y, Maki T, Takahashi R, Ihara M. The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice. Int J Mol Sci. 2019;20(10) Read more
Hasegawa T, Komagata M, Hamasaki A, Harada N, Seino Y, Inagaki N. Solid-phase extraction treatment is required for measurement of active glucagon-like peptide-1 by enzyme-linked immunosorbent assay kit affected by heterophilic antibodies. J Diabetes Investig. 2019;10(2):302-308. Read more
Otsuka Y, Yamaguchi S, Furukawa A, Kosuda M, Nakazaki M, Ishihara H. Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes. Endocr J. 2015;62(2):133-43. Read more
Masajtis-zagajewska A, Kurnatowska I, Wajdlich M, Jagodzińska M, Nowicki M. Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients. Int Urol Nephrol. 2013;45(6):1733-40. Read more
Bligh HF, Godsland IF, Frost G, et al. Plant-rich mixed meals based on Palaeolithic diet principles have a dramatic impact on incretin, peptide YY and satiety response, but show little effect on glucose and insulin homeostasis: an acute-effects randomised study. Br J Nutr. 2015;113(4):574-84. Read more
Sakata S, Katsumi S, Mera Y, et al. Mechanism of action of hypoglycemic effects of an intestine-specific inhibitor of microsomal triglyceride transfer protein (MTP) in obese rats. J Pharmacol Sci. 2015;127(1):103-8. Read more
Ma M, Hasegawa Y, Koibuchi N, et al. DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice. Cardiovasc Diabetol. 2015;14:54. Read more
Shimasaki T, Masaki T, Mitsutomi K, et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet-induced obesity. PLoS ONE. 2013;8(5):e63626. Read more
Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014;13:154. Read more
Koibuchi N, Hasegawa Y, Katayama T, et al. DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure. Cardiovasc Diabetol. 2014;13:157. Read more